Rocio Gonzalez-Conejero

List of Publications by Year in Descending Order

112 papers	2,392 citations	28 h-index	43 g-index
112 ext. papers	2,694 ext. citations	5.5 avg, IF	4.24 L-index

#	Paper	IF	Citations
112	Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer. *Cancers*, **2022**, 14, 2390	6.6	
111	miR-146a in Cardiovascular Diseases and Sepsis: An Additional Burden in the Inflammatory Balance?. *Thrombosis and Haemostasis*, **2021**, 121, 1138-1150	7	2
110	The PI3K□nhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
109	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. *Haematologica*, **2021**, 106, 1636-1646	6.6	15
108	Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVID-19 outcomes. *Clinical and Translational Medicine*, **2021**, 11, e268	5.7	7
107	MicroRNAs as New Regulators of Neutrophil Extracellular Trap Formation. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
106	miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. *Leukemia*, **2020**, 34, 2648-2659	10.7	9
105	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. *Thrombosis Research*, **2020**, 185, 119-124	8.2	11
104	Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?. *Platelets*, **2020**, 31, 906-912	3.6	3
103	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5
102	Neutrophil extracellular trap components increase the expression of coagulation factors. *Biomedical Reports*, **2019**, 10, 195-201	1.8	9
101	MicroRNAs as potential regulators of platelet function and bleeding diatheses. *Platelets*, **2019**, 30, 803-808	3.6	8
100	Identification of Circulating microRNA Signatures As Potential Noninvasive Biomarkers for Prediction to Response to Extracorporeal Photoapheresis in Patients with Graft Versus Host Disease. *Blood*, **2019**, 134, 4466-4466	2.2	0
99	Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 1477-1491	6.1	12
98	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. *European Journal of Clinical Investigation*, **2018**, 48, e12929	4.6	1
97	microRNAs in the haemostatic system: More than witnesses of thromboembolic diseases?. *Thrombosis Research*, **2018**, 166, 1-9	8.2	18
96	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 892-902	9.4	34

95	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. *Haematologica*, **2018**, 103, 908-918	6.6	21
94	miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. *PLoS ONE*, **2018**, 13, e0198932	3.7	12
93	rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling. *Blood*, **2018**, 132, 3072-3072	2.2	
92	Regulation of TFPI expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. *Scientific Reports*, **2017**, 7, 43500	4.9	16
91	Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. *Journal of Autoimmunity*, **2017**, 82, 31-40	15.5	50
90	Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study. *Thrombosis and Haemostasis*, **2016**, 115, 117-25	7	9
89	MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha. *PLoS ONE*, **2016**, 11, e0154751	3.7	13
88	The role of microRNA-27a/b and microRNA-494 in estrogen-mediated downregulation of tissue factor pathway inhibitor *Journal of Thrombosis and Haemostasis*, **2016**, 14, 1226-37	15.4	20
87	Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients*Scientific Reports*, **2016**, 6, 31375	4.9	33
86	Uniparental disomy causes deficiencies of vitamin K-dependent proteins. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 2410-2418	15.4	5
85	CALU polymorphism A29809G affects calumenin availability involving vascular calcification. *Journal of Molecular and Cellular Cardiology*, **2015**, 82, 218-27	5.8	7
84	Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNF *Arthritis Research and Therapy*, **2015**, 17, 49	5.7	117
83	Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. *Human Reproduction*, **2015**, 30, 2292-302	5.7	39
82	Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, 595-602	4	11
81	Regulation of coagulation factor XI expression by microRNAs in the human liver. *PLoS ONE*, **2014**, 9, e111713	3.7	24
80	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. *Thrombosis and Haemostasis*, **2014**, 112, 781-8	7	27
79	Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. *Pharmacogenomics*, **2014**, 15, 987-96	2.6	8
78	Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. *Annals of Hematology*, **2014**, 93, 243-7	3	12

77	Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study. *BMC Cancer*, **2013**, 13, 228	4.8	11
76	Control of post-translational modifications in antithrombin during murine post-natal development by miR-200a. *Journal of Biomedical Science*, **2013**, 20, 29	13.3	10
75	Creating a genotype-based dosing algorithm for acenocoumarol steady dose. *Thrombosis and Haemostasis*, **2013**, 109, 146-53	7	29
74	miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle. *Molecular Medicine*, **2013**, 18, 1466-72	6.2	31
73	Novel associations of VKORC1 variants with higher acenocoumarol requirements. *PLoS ONE*, **2013**, 8, e64469	3.7	12
72	Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: influence of geographical factors and occupational exposure. *Molecular Carcinogenesis*, **2012**, 51, 508-13	5	8
71	Influence of the F12 -4 C>T polymorphism on hemostatic tests. *Blood Coagulation and Fibrinolysis*, **2010**, 21, 632-9	1	10
70	Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. *Thrombosis and Haemostasis*, **2010**, 104, 650-2	7	2
69	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. *Annals of Medicine*, **2010**, 42, 562-75	1.5	10
68	Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. *Thrombosis Research*, **2010**, 126, e46-50	8.2	14
67	CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. *Annals of Medicine*, **2010**, 42, 439-46	1.5	7
66	Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. *Annals of Hematology*, **2010**, 89, 1147-54	3	3
65	Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1012-7	15.4	16
64	Genotype-phenotype relationship for six common polymorphisms in genes affecting platelet function from 286 healthy subjects and 160 patients with mucocutaneous bleeding of unknown cause. *British Journal of Haematology*, **2009**, 146, 95-103	4.5	13
63	Pharmacogenetics in cardiovascular antithrombotic therapy. *Journal of the American College of Cardiology*, **2009**, 54, 1041-57	15.1	81
62	Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. *Blood*, **2009**, 113, 4977-9	2.2	67
61	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. *Thrombosis and Haemostasis*, **2009**, 101, 483-486	7	29
60	Implications of pharmacogenetics for oral anticoagulants metabolism. *Current Drug Metabolism*, **2009**, 10, 632-42	3.5	12

59	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. *Thrombosis and Haemostasis*, **2009**, 101, 483-6	7	1
58	Gamma-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. *Thrombosis Research*, **2008**, 122, 429-31	8.2	4
57	Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk. *Annals of Medicine*, **2008**, 40, 553-9	1.5	13
56	Coexistence of three genetic risk factors in a Spanish thrombophilic family: Factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency. *Thrombosis and Haemostasis*, **2007**, 97, 153-155	7	4
55	Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. *British Journal of Haematology*, **2007**, 137, 99-108	4.5	43
54	Prognostic value of annexin A5 -1 C/T polymorphism in a long term follow-up after premature myocardial infarction. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 862-3	15.4	6
53	The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1701-6	15.4	31
52	The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. *Haematologica*, **2007**, 92, 513-8	6.6	32
51	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. *Blood*, **2007**, 109, 4258-63	2.2	90
50	A novel mutation in the antithrombin gene (insT 7429-30) causes superior mesenteric vein thrombosis. *Thrombosis Research*, **2007**, 119, 793-6	8.2	3
49	Coexistence of three genetic risk factors in a Spanish thrombophilic family: Factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency. *Thrombosis and Haemostasis*, **2007**, 97, 153-5	7	2
48	Latent and polymeric antithrombin: clearance and potential thrombotic risk. *Experimental Biology and Medicine*, **2007**, 232, 219-26	3.7	10
47	Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. *Stroke*, **2006**, 37, 2288-93	6.7	47
46	Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated. *Future Cardiology*, **2006**, 2, 197-203	1.3	
45	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. *Blood*, **2006**, 108, 177-83	2.2	53
44	Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?. *Stroke*, **2005**, 36, 276-80	6.7	121
43	A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. *Journal of the American College of Cardiology*, **2005**, 45, 25-9	15.1	22
42	Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis. *British Journal of Haematology*, **2005**, 129, 561-2; author reply 562	4.5	8

41	Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. *Thrombosis and Haemostasis*, **2005**, 94, 1294-9	7	23
40	Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. *Haematologica*, **2005**, 90, 421-3	6.6	17
39	Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. *Circulation*, **2004**, 110, 1303-7	16.7	37
38	Platelet GP IIIa polymorphism HPA-1 (PlA) protects against subarachnoid hemorrhage. *Stroke*, **2004**, 35, 2282-6	6.7	23
37	Genetic variants of the extra-large stimulatory Gs protein alpha-subunit and risk of thrombotic and haemorrhagic disorders. *British Journal of Haematology*, **2004**, 125, 621-8	4.5	4
36	Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 931-9	15.4	48
35	Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 2264-5	15.4	4
34	Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. *Journal of Molecular and Cellular Cardiology*, **2004**, 37, 699-704	5.8	31
33	Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. *American Heart Journal*, **2004**, 148, 602-5	4.9	16
32	Mutation analysis of HPS1, the gene mutated in Hermansky-Pudlak syndrome, in patients with isolated platelet dense-granule deficiency. *Haematologica*, **2004**, 89, 325-9	6.6	5
31	The -1C>T mutation in the annexin A5 gene does not affect plasma levels of annexin A5. *Blood*, **2003**, 101, 4223-4; author reply 4224-5	2.2	12
30	Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation. *Breast Cancer Research and Treatment*, **2003**, 80, 145-54	4.4	21
29	Role of factor XIII Val34Leu polymorphism in patients . *American Journal of Cardiology*, **2003**, 91, 1242-5	3	22
28	Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. *Translational Research*, **2003**, 142, 298-305		17
27	Molecular, ultrastructural and functional characterization of a Spanish family with Hermansky-Pudlak syndrome: role of insC974 in platelet function and clinical relevance. *British Journal of Haematology*, **2003**, 123, 132-8	4.5	9
26	Polymorphisms of platelet adhesive receptors: do they play a role in primary intracerebral hemorrhage?. *Cerebrovascular Diseases*, **2003**, 15, 51-5	3.2	17
25	Prothrombin A19911G and G20210A polymorphismsQrole in thrombosis. *British Journal of Haematology*, **2002**, 118, 610-4	4.5	28
24	Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists. *Blood Coagulation and Fibrinolysis*, **2002**, 13, 95-103	1	2

23	A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. *Blood*, **2002**, 100, 2081-6	2.2	10
22	Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. *Blood*, **2001**, 97, 2979-82	2.2	72
21	Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. *British Journal of Haematology*, **2001**, 115, 969-76	4.5	33
20	Role of factor XIII Val 34 Leu polymorphism in patients with migraine. *Cephalalgia*, **2001**, 21, 837-41	6.1	10
19	Platelet GP Ib/IX/V complex: physiological role. *Journal of Physiology and Biochemistry*, **2000**, 56, 355-65	5	10
18	The TFPI 536C ->T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis. *Thrombosis and Haemostasis*, **2000**, 83, 787-788	7	27
17	Evaluation of leukocyte-depleted platelet concentrates obtained by in-line filtration. *Vox Sanguinis*, **2000**, 78, 235-41	3.1	8
16	Factor XIII Val34Leu polymorphism in primary intracerebral haemorrhage. *The Hematology Journal*, **2000**, 1, 269-73		8
15	Prothrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease. *Headache*, **1999**, 39, 486-9	4.2	29
14	Quality assessment of platelet concentrates supplemented with second-messenger effectors. *Transfusion*, **1999**, 39, 135-43	2.9	24
13	The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPA-5 polymorphisms. *Transfusion*, **1999**, 39, 372-8	2.9	39
12	Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. *Bone Marrow Transplantation*, **1999**, 23, 621-4	4.4	11
11	Platelet cryopreservation using a reduced dimethyl sulfoxide concentration and second-messenger effectors as cryopreserving solution. *Cryobiology*, **1999**, 39, 1-12	2.7	15
10	A radioreceptor assay for mass measurement of inositol (1,4,5)-trisphosphate using saponin-permeabilized outdated human platelets. *Analytical Biochemistry*, **1998**, 256, 117-21	3.1	1
9	New alleles of the platelet glycoprotein Ibalpha gene. *British Journal of Haematology*, **1998**, 103, 997-1003	4.5	20
8	Migraine and prothrombotic genetic risk factors. *Cephalalgia*, **1998**, 18, 257-60	6.1	31
7	Polymorphisms of Platelet Membrane Glycoprotein Ib? Associated With Arterial Thrombotic Disease. *Blood*, **1998**, 92, 2771-2776	2.2	155
6	Polymorphisms of Platelet Membrane Glycoprotein Ib? Associated With Arterial Thrombotic Disease. *Blood*, **1998**, 92, 2771-2776	2.2	3

5	Factor-V (Arg506 --> Gln) mutation in ischemic cerebrovascular disease. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1997**, 27, 105-11		
4	The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. *British Journal of Haematology*, **1997**, 99, 304-7	4.5	85
3	Comparative study of three methods to detect free plasma antiplatelet antibodies. *Acta Haematologica*, **1996**, 96, 135-9	2.7	5
2	Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts. *British Journal of Haematology*, **1996**, 93, 464-71	4.5	14
1	Detection of Factor V Leiden from a Drop of Blood by PCR-SSCP. *Thrombosis and Haemostasis*, **1996**, 76, 735-737	7	30